Diaceutics Past Earnings Performance

Past criteria checks 0/6

Diaceutics's earnings have been declining at an average annual rate of -56.5%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 16.4% per year.

Key information

-56.5%

Earnings growth rate

-56.6%

EPS growth rate

Life Sciences Industry Growth36.9%
Revenue growth rate16.4%
Return on equity-7.3%
Net Margin-10.9%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Diaceutics PLC (LON:DXRX) Stock Rockets 29% But Many Are Still Ignoring The Company

May 30
Diaceutics PLC (LON:DXRX) Stock Rockets 29% But Many Are Still Ignoring The Company

Diaceutics PLC's (LON:DXRX) Subdued P/S Might Signal An Opportunity

Jan 31
Diaceutics PLC's (LON:DXRX) Subdued P/S Might Signal An Opportunity

Industry Analysts Just Made A Notable Upgrade To Their Diaceutics PLC (LON:DXRX) Revenue Forecasts

Jan 28
Industry Analysts Just Made A Notable Upgrade To Their Diaceutics PLC (LON:DXRX) Revenue Forecasts

Estimating The Intrinsic Value Of Diaceutics PLC (LON:DXRX)

Jul 24
Estimating The Intrinsic Value Of Diaceutics PLC (LON:DXRX)

Would Shareholders Who Purchased Diaceutics' (LON:DXRX) Stock Year Be Happy With The Share price Today?

Feb 04
Would Shareholders Who Purchased Diaceutics' (LON:DXRX) Stock Year Be Happy With The Share price Today?

Here's Why We Don't Think Diaceutics's (LON:DXRX) Statutory Earnings Reflect Its Underlying Earnings Potential

Dec 31
Here's Why We Don't Think Diaceutics's (LON:DXRX) Statutory Earnings Reflect Its Underlying Earnings Potential

Do Insiders Own Lots Of Shares In Diaceutics PLC (LON:DXRX)?

Nov 27
Do Insiders Own Lots Of Shares In Diaceutics PLC (LON:DXRX)?

Revenue & Expenses Breakdown

How Diaceutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

AIM:DXRX Revenue, expenses and earnings (GBP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2426-3260
31 Mar 2425-2250
31 Dec 2324-2230
30 Sep 2323-1210
30 Jun 23220200
31 Mar 23210180
31 Dec 22201160
30 Sep 22180150
30 Jun 22160140
31 Mar 22150130
31 Dec 21141120
30 Sep 21140120
30 Jun 2113-1110
31 Mar 21130110
31 Dec 20130100
30 Sep 2014290
30 Jun 2014390
31 Mar 2014290
31 Dec 1913080
30 Sep 1912070
30 Jun 1911060
31 Mar 1911060
31 Dec 1810160
31 Dec 177140
31 Dec 165120
31 Dec 151010

Quality Earnings: DXRX is currently unprofitable.

Growing Profit Margin: DXRX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: DXRX is unprofitable, and losses have increased over the past 5 years at a rate of 56.5% per year.

Accelerating Growth: Unable to compare DXRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DXRX is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-9.9%).


Return on Equity

High ROE: DXRX has a negative Return on Equity (-7.34%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies